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Abstract
Background: Functional status assessment is common in many cardiovascular diseases but it has
undergone limited study in the setting of acute heart failure (AHF). Accordingly, we performed a pilot
study of the feasibility of the six-minute walk test (6MWT) at the emergency department (ED)
presentation and through the hospitalization in patients with AHF. Methods and Results: From November
2014 to February 2015, we conducted a multicenter, observational study of ED patients, aged 18–85 years,
whose primary ED admission diagnosis was AHF. Other criteria for enrollment included a left ventricular
ejection fraction ≤40%, systolic blood pressure between 90 and 170 mmHg, and verbal confirmation that
the patient was able to walk >30 m at the baseline, prior to ED presentation. Study teams were uniformly
trained to administer a 6MWT. Patients underwent a baseline 6MWT within 24 h of ED presentation (Day
1) and follow-up 6MWTs at 24 (Day 2), 48 (Day 3), and 120 h (Day 5). A total of 46 patients (65.2%
male, 73.9% African American) had a day one mean walk distance of 137.3 ± 78 m, day 2 of 170.9 ± 100
m, and day 3 of 180.8 ± 98 m. The 6MWT demonstrated good reproducibility, as the distance walked on
the first 6MWT on Day 3 was similar to the distance on the repeated 6MWT the same day. Conclusions:
Our pilot study demonstrates the feasibility of the 6MWT as a functional status endpoint in AHF patients.
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A larger study in a more demographically diverse cohort of patients is necessary to confirm its utility and
association with 30-day heart failure (HF) events.
Keywords: 6 min walk test, acute heart failure, emergency department
1. Background
Quality of life is critical to patients’ health and well-being. While reducing readmissions and mortality
remain important endpoints, maintaining or improving the quality of life may be more important to
patients. For heart failure (HF) patients, some would trade life years for a better life quality [1]. One key
component of quality of life for HF patients is functional ability, such as maintaining the activities of daily
living and self-care.
Functional status assessment is commonly used in chronic HF studies and other cardiovascular diseases
[2]. While subjective symptom assessments are common in acute heart failure (AHF), however, clinical
trials and formal functional status assessment are not [3,4]. Ideally, AHF patients return to their baseline
functional capacity prior to discharge. However, this is seldom rigorously evaluated. In chronic HF, the 6
min walk test (6MWT) is a validated measure of functional capacity, assessing the distance a patient can
walk in 6 min, performed at the patient’s intrinsic walking speed, including all patient-determined stops.
Changes in 6MWT distance as a result of therapeutic interventions predict rehospitalizations and mortality
[5,6,7]. However, the feasibility of performing baseline and serial 6MWT in AHF, to assess the potential
response to therapy has not been well studied [8]. We performed a pilot study to determine the feasibility
of performing the 6MWT in AHF patients in the emergency department (ED) and continuing through
hospitalization.
2. Methods
Study Design and Setting: From November 2014 to February 2015, we conducted a multicenter
observational study of ED patients, aged 18–85 years, whose primary ED admission diagnosis was AHF.
Patients were enrolled at six academic, urban hospitals in the United States. The study and all associated
procedures were approved by local and/or central IRBs/ethics committees per each participating
institution, and all patients provided written informed consent.
Participants: AHF was established at each institution by the ED provider using history and physical exam
findings, congestion on chest radiograph, and elevated levels of natriuretic peptides. This diagnosis was
confirmed with the treating physician by the study team prior to approaching the patient. All patients were
enrolled within 24 h of ED presentation, though the investigators were encouraged to approach the patients
as soon as AHF was confirmed by the provider. The remaining inclusion criteria included a left ventricular
ejection fraction (LVEF) ≤40% (as assessed by echocardiography, MRI, MUGA, or right heart
catheterization within the 6 months prior to the ED presentation), systolic blood pressure (SBP) between
90 and 170 mmHg, and verbal confirmation that the patient was able to walk at least 30 m prior to
developing AHF symptoms leading to the index presentation. Patients were excluded who had other
significant non-cardiac limitations to their ambulatory capacity, who were considered likely to undergo an
invasive procedure within three days of study enrollment or who had eGFR <30 mL/min/1.73 m .
Study Procedures: Research teams at all six institutions were uniformly trained by using standardized
methods by study personnel from the Colorado Prevention Center Clinical Research, a group with
extensive prior 6MWT trial experience [9]. Study teams reviewed vital signs and the most recent
laboratories prior to commencing the 6MWT to identify clinically significant changes that might preclude
performance of the 6MWT, such as the orthostatic or new symptomatic systolic blood pressure less than 90
mmHg. Per eligibility criteria, no patient with a SBP <90 mmHg was allowed to participate. Furthermore,
the investigators were specifically told to exclude patients with any other significant lab abnormalities that
would increase the risk associated with the 6MWT. Oxygen therapy or walking aids required at baseline
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were continued in a similar fashion in all subsequent tests for any given patient. Patients enrolled in the
study underwent a baseline (Day 1) 6MWT as early as possible while in the ED; serial 6MWTs were
performed at 24 (Day 2), 48 (Day 3), and 120 h (Day 5; or at discharge, if sooner) during the patient’s
hospital stay. At the 48-h time point, two sequential 6MWTs were performed, separated by a 30-min rest
between the tests. Distance to the first stop was defined as the total distance (meters) walked by the patient
before indicating they needed to rest. Prior to conducting the 6MWT, patient safety was assessed by
evaluating the serial vital signs, including assessments immediately preceding the performance of the
6MWT. Routine laboratories, BNP (B-type natriuretic peptide) or NTproBNP, and ECGs were monitored
after the 6MWT as well. Data on rehospitalizations and mortality were collected up to Day 35 after
enrollment, or 30 days after discharge from the hospital if the index length of stay was less than 5 days.
Statistical Analysis: The sample size for this pilot observational study was based on prior observations.
Approximately 50–70 patients per arm [10] have previously been required to demonstrate a statistically
significant change in the 6MWT due to an intervention in other ill patient populations. Patients who
declined any attempt to perform the 6MWT (outside of the baseline) based on personal preference were
not included in the analysis for that specific time point. A distance of 0 m for the 6MWT at any given time
point was imputed to patients who were willing but unable to perform the 6MWT at that time point due to
deteriorations in clinical status. Means and other descriptive statistics were calculated, and a correlation
between baseline 6MWT and subsequent 6MWT performance, hospital length of stay (LOS), BNP levels,
and 30-day events were analyzed using SAS system software (GitHub, Cary, NC, USA), version 9.4 on a
Windows 10 platform. Cox proportional hazards modeling was used to evaluate the association between
6MWT performance and hospital readmission within 30 days.
3. Results
3.1. Participant Characteristics
Figure 1 demonstrates the study allocation of the 51 patients enrolled. There were 15 (29.4%) patients
enrolled at Center 1, 25 (49.0%) at Center 2, 3 (5.9%) at Center 3, one (2.0%) at Center 4, 6 (11.8%) at
Center 5, and one (2.0%) at Center 6. Of the 48 patients with LVEF ≤40%, their mean age was 55.8 ± 12.9
years, 65.2% were male, and 73.9% of patients were African-American (Table 1). Mean LVEF was 24.1 ±
9.2% and mean ED systolic blood pressure was 126.9 ± 19.7 mmHg (range 90–149 mmHg). The mean
time from presentation to performance of the first, baseline 6MWT was 10.8 ± 5.6 h (range 2.1 to 21.8 h).
Forty-six patients had serial walk tests available and were included in the final analysis cohort. The
majority (85%) of patients received intravenous diuretics during their ED stay, while 15% received topical
or sublingual nitrates.
3.2. Safety and Feasibility of 6MWT
Of the 46 total patients, 44 (95.7%) attempted a baseline 6MWT (Day 1). Of these, 21 (45.7%) required at
least one rest stop prior to the end of the 6-min walk period. Fewer patients attempted a 6MWT on Day 2
(n = 38) and Day 3 (n = 28), largely due to early hospital discharge, while a minority were unable to due to
worsening clinical status. Importantly, only 4 patients refused to do a total of 5 of the 154 individual
6MWTs in this study. Of the 32 patients who did not have a Day 5 6MWT, 27 were due to hospital
discharge at day 2 or 3, and only 5 were due to worsening clinical condition. No adverse events were
reported during the performance of the 6MWT. Four adverse events were reported in 4 patients during the
4 h period after the completion of the 6MWT—1 episode of paroxysmal atrial fibrillation with onset ~12
min after the start of the 6MWT, 2 episodes of fever (16–10 min after 6MWT start), and one episode of
acute-on-chronic respiratory failure, 104 min after the start of the 6MWT. No early withdrawal of patients
occurred.
3.3. 6MWT Performance
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At baseline (Day 1), the patients walked a mean of 137.3 ± 78 m. There was no correlation between the
Day 1 total distance walked or the distance to first stop with either LVEF or baseline SBP. On Day 2 (24 h
after the first baseline 6MWT), the mean distance walked was 170.9 ± 100 m (Figure 2). On Day 3 (48 h
after the first 6MWT) the mean distance walked was 180.8 ± 98 m and improved with each day in the
hospital (Figure 3). The 6MWT demonstrated good reproducibility, as the distance walked by the 28
patients on the first 6MWT on Day 3 was similar to the distance on the repeated 6MWT on the same day
(total distance walked 180.8 ± 98.3 m vs. 179.6 ± 96.2 m and distance to first stop 165.5 ± 110 m vs. 172.2
± 102.2 m ) (Figure 4). Similar daily improvements in distance to the first stop were observed. Day 1 mean
distance to the first stop was 112.0 ± 91 m, with an improvement to 152.5 ± 113 m (41.7 ± 71.7 m; p =
0.0013) and 164.4 ± 112 m (55.3 ± 83.8 m; p = 0.0025) on Days 2 and 3, respectively.
3.4. 6MWT Correlation with Biomarkers and Outcomes
Day 1 BNP was not correlated with baseline 6MWT total distance (r  = 0.044, p = 0.23) or distance to first
stop (r  = 0.047, p = 0.22). Changes in the 6MWT from day 1 to day 3 and changes in BNP over the same
time did not correlate. Changes in the total distance and distance to first stop from Day 1 to Day 3
exhibited a non-significant trend toward an inverse correlation with length of stay of the index admission
(r = −0.34, p = 0.09). Exploratory analyses for the relationship between the baseline 6MWT and the
probability of readmission (n = 9 patients) within 30 days suggest that a higher baseline 6MWT was
associated with a lower likelihood of readmission at 30 days (p = 0.06).
4. Discussion
The results of our pilot study suggests the following: (1) the performance of a 6MWT is feasible for AHF
patients, starting in the ED and continuing throughout hospitalization, as a minority of the 154 individual
6MWT’s were unable to be performed due to the worsening clinical status or patient refusal; (2) the
6MWT distance improves as patients receive AHF therapy during hospitalization; and, (3) the 6MWT
distance is reproducible, as suggested by similar total distances when duplicate 6MWT testing occurred in
the same subject within the same day. Six minute walk test performance in these patients may be a
function of the patient’s baseline status, a response to therapy, or both. When compared to other critically
ill HF patients, these AHF patients appear to have a lower baseline 6MWT distance (mean 182 m vs. 137
m respectively), and a smaller variability (SD of 140 m vs. 78 m, respectively) [11]. At lower 6MWT
distances, the primary limitation to ambulation may be the patient’s physical status, and ambulatory
distance may be less susceptible to verbal encouragement.
These pilot results suggest that the 6MWT could be utilized as a patient-centric endpoint in AHF studies.
Our study suggests that the 6MWT is feasible in AHF patients, as early as 2.1 h after presentation (mean
10.8 h). Even patients who may be unable to walk at the baseline may improve sufficiently over their
hospitalization, enabling the subsequent 6MWT assessments to be feasible. Thus, it would be important to
include all of patients who indicate that they can walk at baseline, even if when they are approached for
enrollment they are too acutely ill to perform a 6MWT. Similarly, when patient’s 6MWT time worsens or
they become unable to perform the test, this could be a sign of a lack of response to therapy. It is currently
unclear if an absolute minimum distance or a relative improvement over baseline 6MWT distance might be
an appropriate predictor of other clinical outcomes. Larger studies are needed to determine whether the
6MWT distance is associated with both short- and long-term outcomes. While we saw a trend toward an
association between 6MWT distance and 30-day events, we only had 9 patients who experienced 30-day
readmission. As patients received AHF therapy, their walk distance improved, suggesting that this could be
an objective marker to determine the optimal endpoints of therapy. If the 6MWT is found to be feasible in
a larger cohort of patients, and associated with clinical events, collaboration across hospitals, and between
investigators would be important to ensure its successful implementation.
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Compared to the RED ROSE studies, where 1/3rd of patients either were unable or unwilling to perform
bedside stepping in place, the 6MWT was indeed feasible in our cohort of AHF patients [12]. While the
reasons to perform an initial 6MWT are multifactorial, the baseline differences between our study and
RED ROSE are considerable. Our patients’ mean age was over 10 years younger, with a much higher
proportion of African Americans, and a 10 mmHg higher mean systolic blood pressure. However,
enrolling subjects in the ED setting supports the feasibility of performing functional testing acutely. Our
pilot study, albeit limited by the small number of patients, also highlights the heterogeneity of the AHF
population.
While we were limited by the sample size, we did not see an association between changes in natriuretic
peptide levels and 6MWT distance. There could be several reasons for this. Natriuretic peptide levels have
wide daily variation and are a lagging indicator when considering AHF resolution. In stable outpatients
with chronic HF, significant increases in BNP are not necessarily predictive of AHF. Further, tailoring
therapy based on natriuretic peptide levels have yielded mixed results. Similarly, even significant increases
in BNP levels in stable outpatients with HFrEF have not been predictive of subsequent AHF [13]. There
was significant variability in natriuretic peptide levels within each patient in our study, and a decrease was
not observed in all patients despite treatment and symptom improvement. This has been seen in prior ED-
based AHF studies where serial BNP levels were measured. There was a mean change of 200–350 pg/mL
in BNP during hospitalization, yet none of these changes were helpful in predicting hospital LOS, 30-day
readmission, or all-cause mortality [14].
Limitations: While our pilot study suggests that the 6MWT is feasible and reproducible in AHF patients
there were several limitations to consider. We enrolled a relatively small number of patients who
experienced few 30-day events. We also only enrolled HFrEF patients as this study was designed to use the
6MWT in a subsequent clinical trial of HFrEF patients. There may be differences in HFrEF and HFpEF
patients related to the changes in their 6MWT as they receive AHF therapy. Our clinical sites had a large
proportion of younger, African American patients, so incorporating a more demographically diverse
population of patients to ensure generalizability would be important. If illness severity or comorbidities
differ in future studies than this may impact the proportion of patients who could complete all of the
administered tests. Our study’s small sample size limited our ability to investigate this. The number of
people who did a test on any given day is not the same as the number of people who did all 3 days of tests,
as different patients missed different days. We did not track the reasons for the refusal to be in the study,
and it would be good to quantify the impact of disease severity on patient participation in future studies.
In summary, our pilot study suggests that the 6MWT is both feasible and safe in patients with AHF. The
majority of patients were able to perform this test, starting in the ED, and continuing throughout
hospitalization. A larger study is necessary to evaluate its utility in a more demographically diverse
population of patients, including those with preserved ejection fraction, and determine its relationship to
longer-term outcomes such as HF readmission and mortality.
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Figure 1
Enrollment and patient flow through the study.
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Figure 2
Mean six-minute walk test (6MWT) distance on Day 1 correlated with 6MWT distance on Day 2.
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Figure 3
6MWT distance (meters) from day 1 through the end of Day 5. Only 16 subjects were still hospitalized at Day 5.
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Figure 4
Difference (in meters) between duplicated 6-min walk tests on Day 3.
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Table 1
Demographics and baseline characteristics of the study cohort.
Parameter N * (%) Mean (SD)
Parameter N * (%) Mean (SD)
Age 48 55.6 (13.0)
Gender
 Male 32 (67)
 Female 16 (33)
Race
 White 13 (27)
 Black/African-American 35 (73)
Primary HF Etiology
 Ischemic 15 (31)
 Dilated 18 (28)
 Non-ischemic 11 (23)
 Chemotherapy 2 (4.2)
 Idiopathic 1 (2.1)
 Combined Ischemic(MI) & Non-ischemic(HTN) 1 (2.1)
NYHA Class
 III 43 (90)
 IV 3 (6.3)
 Unknown 2 (4.2)
History of Angina
 Yes 8 (17)
 No 40 (83)
LVEF by echocardiogram 48 24 (9.1)
eGFR 46 71 (22.0)
Baseline SBP (mmHg) 48 127 (19)
Baseline DBP (mmHg) 48 78 (15)
Baseline HR (bpm) 48 86 (16)
Weight (kg) 47 92.8 (30.1)
IV Diuretics 41 (65)
Topical/Sublingual Nitroglycerin 7 (15)
* Two patients who left AMA within 24 h of presentation were included in this Table but excluded from subsequent analyses
for having only one data point.
Articles from Journal of Clinical Medicine are provided here courtesy of Multidisciplinary Digital Publishing
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